drugset
drugset / Trial / NCT05917782

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

NCT05917782 ↗

Phase 1 Completed 324 enrolled Connect Biopharm LLC
RandomizedParallel-groupOpen-labelBasic science

Summary

This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.

Timeline

Start
2023-07-18
Primary completion
2023-10-06
Completion
2023-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CBP-201 Unknown 150 mg Subcutaneous
Subject CBP-201 Unknown 300 mg Subcutaneous

Indications

No indication recorded.